Indications & Dose:

Type 2 diabetes mellitus in combination with metformin or a sulfonylurea, or both, in patients who have not achieved adequate glycaemic control with these drugs alone or in combination  Type 2 diabetes mellitus in combination with basal insulin or both metformin and pioglitazone when dual therapy with these drugs fails to achieve adequate glycaemic control l

• BY SUBCUTANEOUS INJECTION

Adult: Initially 0.6 mg once daily for at least 1 week, then increased to 1.2 mg once daily for at least 1 week, then increased if necessary up to 1.8 mg once daily

Contraindications:

Diabetic gastroparesis . inflammatory bowel disease . ketoacidosis . moderate to severe congestive heart failure—no information available 

Cautions:

 History of pancreatitis . mild congestive heart failure—limited experience . thyroid disease

Precautions:

Interaction:

Warnings:

Adverse Effects:

Lactations:

Special Precautions:

Counselling:

Side Effects Or Adverse Reactions:

Patient And Carer Advice: